Kymera Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $82.2 million, compared to a net loss of $62.5 million for the same period in 2024. For the nine months ended September 30, 2025, the company recorded a net loss of $224.4 million, up from $153.1 million in the prior year. Collaboration revenue for the third quarter was $2.8 million, a decrease from $3.7 million in the same quarter last year, while total revenue for the nine months was $36.3 million, down from $39.7 million.
Operating expenses for the third quarter increased to $95.3 million from $75.9 million in the previous year, driven primarily by a rise in research and development costs, which reached $74.1 million, up from $60.4 million. The increase in R&D expenses was attributed to heightened investment in the company's STAT6 program and overall growth in personnel and operational costs. General and administrative expenses also rose to $17.3 million from $15.5 million, reflecting increased legal and professional service fees.
Kymera's total assets as of September 30, 2025, amounted to $1.1 billion, an increase from $978.0 million at the end of 2024. The company held cash, cash equivalents, and marketable securities totaling $978.7 million, which it believes will be sufficient to fund operations into the second half of 2028. The increase in total assets was supported by a successful follow-on public offering in June 2025, which generated approximately $288.4 million in gross proceeds.
Strategically, Kymera has made significant advancements in its collaboration agreements, including a new partnership with Gilead Sciences to develop molecular glue degraders for cyclin-dependent kinase 2 (CDK2). This agreement includes a $40 million upfront payment and potential milestone payments totaling up to $665 million. Additionally, the company continues its collaboration with Sanofi on drug candidates targeting IRAK4, with Sanofi planning to advance one of the candidates into clinical testing in 2026.
Looking ahead, Kymera anticipates continued investment in its research and development activities, particularly in its immunology programs. The company aims to advance at least one new molecular entity into clinical testing annually and is focused on addressing significant unmet medical needs in the treatment of immune-inflammatory diseases. However, the company acknowledges the ongoing risks associated with product development and the need for substantial additional funding to support its growth strategy.
About Kymera Therapeutics, Inc.
Kymera Therapeutics is a biopharmaceutical company focused on developing targeted protein degradation therapies for immune-inflammatory diseases. Its pipeline includes oral small molecules targeting STAT6, TYK2, and IRAK4, aiming to treat conditions like atopic dermatitis, asthma, and hidradenitis suppurativa. The company leverages innovative degradation technology to create highly selective, potentially first-in-class medicines with advantages over biologics, targeting high unmet medical needs globally.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.